Biopharmaceutical company Ipsen (Euronext Paris:IPN) (ADR:IPSEY) announced on Monday that the European Commission has approved Kayfanda (odevixibat) for the treatment of cholestatic pruritus in Alagille Syndrome (ALGS) in patients aged 6 months or older.
Kayfanda is a once-daily non-systemic ileal bile acid transport (IBAT) inhibitor.
The decision was based on data from the ASSERT Phase III clinical trial, the first Phase III trial completed in patients with ALGS.
This approval further expands Ipsen's rare cholestatic liver disease portfolio, which also includes Iqirvo (elafibranor) for Primary Biliary Cholangitis.
Johnson & Johnson submits DARZALEX FASPRO supplemental Biologics License Application to FDA
Modalis Therapeutics receives FDA Rare Pediatric Disease designation for MDL-101 in LAMA2-CMD
Adicet Bio announces enrollment for Phase 1 trial to evaluate ADI-001 in autoimmune diseases
Astria Therapeutics secures FDA Orphan Drug Designation for Nnavenibart in HAE treatment
Bristol-Myers Squibb's schizophrenia drug Cobenfy receives US FDA approval
Pharming receives UK marketing authorisation for Joenja
DURECT Corporation announces design of upcoming registrational Phase 3 larsucosterol trial
EydisBio's EYD-001 receives US FDA Orphan Drug Designation
Biocon BIologics unveils new dermatology data at EADV Congress 2024
Implantica advances RefluxStop with CE mark study results and prepares for FDA submission
NeuroSense Therapeutics receives US patent for novel PrimeC formulation
IntraBio's Aqneursa receives US FDA approval
Priovant Therapeutics enrols first patients in brepocitinib CLARITY study
Elevation Oncology's EO-3021 receives US FDA Fast Track designation
Lantern Pharma secures FDA designations for rare paediatric cancers